<DOC>
	<DOCNO>NCT01263236</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability ascend single multiple oral dos LY2940094 healthy male subject .</brief_summary>
	<brief_title>A Study LY2940094 Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Males ethnic origin . Have body mass index ( BMI ) 19.0 30.0 kilogram/square meter ( kg/m² ) , inclusive . Must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation . Have calculate creatinine clearance great 70 milliliter/minute ( mL/min ) . Have venous access sufficient allow blood sample per protocol . Will give write informed consent participate study abide study restriction . Male subject , whose partner willing use appropriate contraception time first dose 3 month final dosing occasion . Have receive prescribed systemic topical medication within 14 day first dose administration Have use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day first dose administration ( exception vitamin/mineral supplement ) unless opinion Investigator medication interfere study procedure compromise safety . Have receive medication , include St John 's Wort , know chronically alter drug absorption elimination process within 30 day first dose administration Currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product concurrently enrol type medical research judge scientifically medically compatible study . Have donate lose 50 499 milliliter ( mL ) whole blood within 30 day , 499 milliliter ( mL ) whole blood within 56 day precede first dose administration . Have significant history drug allergy determine Investigator . Have clinically significant allergic disease ( exclude nonactive hay fever ) , know allergy LY2940094 excipients determine Investigator . Have semireclined blood pressure pulse rate high 130/90 millimeter mercury ( mmHg ) 100 beat per minute ( bpm ) , respectively , low 90/50 millimeter mercury ( mmHg ) 40 beat per minute ( bpm ) , respectively . Consume 28 unit alcohol per week significant history alcoholism drug/chemical abuse/dependence determine Investigator . Have positive urine drug screen alcohol breath test result indicate substance abuse screen admission treatment period . Smoke 10 cigarette equivalent tobacco per day willing avoid smoking duration least 10 hour . With , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , hematological major disorder determine Investigator . Have clinically significant illness within 4 week start dose administration determine Investigator . Have serum hepatitis , carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , positive result test human immunodeficiency virus ( HIV ) antibody . Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk participate study . In addition , subject follow finding exclude : Confirmed Bazett 's correct QT ( QTcB ) interval great 450 millisecond ( msec ) 2 3 electrocardiogram ( ECGs ) . Bundle branch block conduction abnormality ( include 2nd 3rd degree Atrioventricular block , complete leave bundle branch block , complete right bundle branch block WolffeParkinsonWhite Syndrome , define PR le 110 millisecond ( msec ) , confirm repeat electrocardiogram [ ECG ] ) mild firstdegree atrioventricular block ( AV ) block . Irregular rhythms sinus arrhythmia occasional rare supraventricular ectopic beat . History unexplained syncope . Family history unexplained syncope sudden death due long QT syndrome . T wave configuration adequate quality assess QTc interval . Have previously complete withdrawn study . Taking excluded medication discontinue Screening . Have personal family history recurrent seizure complicate febrile seizure . Have history significant brain trauma . Have epileptiform activity baseline electroencephalogram ( EEG ) . The following exclusion criterion apply subject enrol part study involve lumbar puncture ( LP ) procedure Have abnormality lumbar spine determine investigator Have history clinically significant back pain and/or back injury Have evidence history significant active bleeding coagulation disorder Have allergy lidocaine ( Xylocaine® ) derivative Have medical surgical condition LP contraindicate The following exclusion criterion applies subject enrol part study involve alcohol interaction Have intolerance allergy toward alcohol ( symptom may include nausea , flush face , vomit , hypotension ) , opinion investigator , may able tolerate 0.8 gram per kilogram ( g/kg ) alcohol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Depression</keyword>
</DOC>